B-FLEXION Life Sciences to Fully Acquire Radius Health in Major Move
B-FLEXION Life Sciences has recently announced its intention to acquire the outstanding 57% stake in Radius Health, a biopharmaceutical firm renowned for its focus on bone health and related therapeutic fields, notably through its flagship product, TYMLOS (abaloparatide) injection. This strategic move follows three years of impressive growth and operational successes that have been instrumental in positioning Radius as a leader in the osteoporosis treatment market.
The announcement was made by Radius Health, detailing that the shares being acquired were previously held by affiliates of Patient Square Capital and Webster Equity Partners. The acquisition comes on the heels of B-FLEXION and Patient Square's initial purchase of Radius in August 2022 during a take-private transaction. Scott Briggs, CEO of Radius Health, expressed his gratitude towards the support from partners, emphasizing the company's journey of transformation over the past three years. Under their joint stewardship, Radius has sharpened its commercial focus and implemented strategies that have resulted in sustained growth.
Briggs highlighted the pivotal role of TYMLOS in the company's offerings, which caters to patients living with osteoporosis—an often under-treated condition that can greatly affect the quality of life. TYMLOS has been FDA-approved for usage in both postmenopausal women and men at high risk for fractures. Its success reflects Radius's commitment to addressing the urgent needs of patients at risk of osteoporotic fractures, thereby expanding its reach in the healthcare market.
Nithya Desikan, Operating Partner at B-FLEXION Life Sciences and a member of Radius’s board, expressed pride in the significant progress made within the Radius portfolio, noting that the company has established robust commercial capabilities that can further enhance TYMLOS’s impact in the market. Desikan assured that the team at B-FLEXION is focused on continuing the momentum and further developing the existing patient and client relationships that Radius has fostered over the years.
Jim Momtazee, Managing Partner of Patient Square, echoed these sentiments, stating that the transformation sparked at Radius by Scott and his team was noteworthy. He remarked on the positive trajectory described in their initial investment thesis and affirmed that this acquisition aligns with their goal of consolidating ownership, enhancing the company’s potential for future growth.
The transaction is anticipated to be finalized by the end of Q1 2026, with Centerview Partners LLC serving as a financial advisor for Radius Health throughout this process. This acquisition symbolizes B-FLEXION's dedication to strengthening its portfolio in the biopharmaceutical sector, particularly in areas aimed at improving patient outcomes through innovative medical solutions.
As B-FLEXION strides forward, the biopharmaceutical community is keenly observing how this development will influence the industry landscape, particularly for those involved in bone health treatments. With Radius Health at the forefront of osteoporosis therapy through TYMLOS, the future appears promising for both B-FLEXION and its constituents, as they aim to make a significant impact on global health. Through invested resources and shared expertise, the partnership is poised to enhance the efficacy of treatments available to patients, ultimately paving the way for better health outcomes in the realm of orthopedic healthcare.
The announcement was made by Radius Health, detailing that the shares being acquired were previously held by affiliates of Patient Square Capital and Webster Equity Partners. The acquisition comes on the heels of B-FLEXION and Patient Square's initial purchase of Radius in August 2022 during a take-private transaction. Scott Briggs, CEO of Radius Health, expressed his gratitude towards the support from partners, emphasizing the company's journey of transformation over the past three years. Under their joint stewardship, Radius has sharpened its commercial focus and implemented strategies that have resulted in sustained growth.
Briggs highlighted the pivotal role of TYMLOS in the company's offerings, which caters to patients living with osteoporosis—an often under-treated condition that can greatly affect the quality of life. TYMLOS has been FDA-approved for usage in both postmenopausal women and men at high risk for fractures. Its success reflects Radius's commitment to addressing the urgent needs of patients at risk of osteoporotic fractures, thereby expanding its reach in the healthcare market.
Nithya Desikan, Operating Partner at B-FLEXION Life Sciences and a member of Radius’s board, expressed pride in the significant progress made within the Radius portfolio, noting that the company has established robust commercial capabilities that can further enhance TYMLOS’s impact in the market. Desikan assured that the team at B-FLEXION is focused on continuing the momentum and further developing the existing patient and client relationships that Radius has fostered over the years.
Jim Momtazee, Managing Partner of Patient Square, echoed these sentiments, stating that the transformation sparked at Radius by Scott and his team was noteworthy. He remarked on the positive trajectory described in their initial investment thesis and affirmed that this acquisition aligns with their goal of consolidating ownership, enhancing the company’s potential for future growth.
The transaction is anticipated to be finalized by the end of Q1 2026, with Centerview Partners LLC serving as a financial advisor for Radius Health throughout this process. This acquisition symbolizes B-FLEXION's dedication to strengthening its portfolio in the biopharmaceutical sector, particularly in areas aimed at improving patient outcomes through innovative medical solutions.
As B-FLEXION strides forward, the biopharmaceutical community is keenly observing how this development will influence the industry landscape, particularly for those involved in bone health treatments. With Radius Health at the forefront of osteoporosis therapy through TYMLOS, the future appears promising for both B-FLEXION and its constituents, as they aim to make a significant impact on global health. Through invested resources and shared expertise, the partnership is poised to enhance the efficacy of treatments available to patients, ultimately paving the way for better health outcomes in the realm of orthopedic healthcare.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.